Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on year to $207.7 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.8% below analysts’ estimates. Its GAAP loss of $0.04 per share was $0.02 below analysts’ consensus estimates.
Is now the time to buy SUPN? Find out in our full research report (it’s free for active Edge members).
Supernus Pharmaceuticals (SUPN) Q1 CY2026 Highlights:
- Revenue: $207.7 million vs analyst estimates of $192.9 million (38.6% year-on-year growth, 7.7% beat)
- EPS (GAAP): -$0.04 vs analyst estimates of -$0.02 ($0.02 miss)
- Adjusted EBITDA: $54.83 million vs analyst estimates of $27.5 million (26.4% margin, 99.4% beat)
- The company reconfirmed its revenue guidance for the full year of $855 million at the midpoint
- Operating Margin: -4%, up from -6.8% in the same quarter last year
- Market Capitalization: $2.83 billion
StockStory’s Take
Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth products and the resumption of new patient initiations for Onepco. CEO Jack Khattar highlighted the strong rebound for Onepco, noting that prescription activity in March surpassed pre-supply constraint levels. The company also pointed to notable performance from Zirzuve and Kelli, with broader prescriber adoption and expanding patient reach. Management credited the recovery in Onepco and the continued expansion of their CNS portfolio as central to the quarter’s outperformance.
Looking ahead, Supernus Pharmaceuticals’ guidance emphasizes continued investment in both commercial execution and pipeline development. Management expects that resolving supply chain constraints and bringing a second supplier for Onapro online will be critical for meeting future demand, particularly as they target regulatory submission later this year. CEO Jack Khattar stated, “We feel pretty good about the rebound in the business…with demand continuing to be strong,” but also acknowledged the need to monitor patient conversions and streamline onboarding. The company’s outlook is further shaped by ongoing R&D activities across multiple late-stage programs, which management believes will support longer-term growth.
Key Insights from Management’s Remarks
Management pointed to strong demand for core products and successful mitigation of supply constraints as key factors behind the quarter’s revenue growth, while also noting that higher SG&A expenses related to collaborations affected profitability metrics.
-
Onepco recovery underway: Following the resumption of new patient initiations in February, Onepco prescriptions and prescriber activity rebounded, with March metrics surpassing levels seen before supply constraints. Management emphasized ongoing efforts to minimize patient drop-off during onboarding, citing that typically 40-45% of patients are converted to therapy, while 55-60% are lost in the process, and highlighting process improvements as priorities.
-
Zirzuve and collaboration revenue growth: The company reported significant collaboration revenues from Zirzuve, with U.S. sales doubling year-over-year and a broader base of prescribers. Management highlighted that only a fraction of the target patient population has been reached so far, leaving room for further penetration.
-
Kelli’s adult market momentum: Kelli experienced robust adoption in the adult segment, now outpacing its pediatric use for the first time. Management attributed this to strategic resource shifts and the product’s ability to offer all-day symptom control, which is particularly valued by adult patients.
-
Gocovri’s steady performance: Gocovri delivered double-digit sales growth, supported by a 7% increase in prescriptions. Management views this as evidence of sustained demand in its target indications amidst a competitive neurology landscape.
-
Elevated operating expenses: Higher selling, general, and administrative costs—primarily stemming from expanded collaboration efforts—offset some of the revenue gains and contributed to a GAAP operating loss, though margins improved year-over-year.
Drivers of Future Performance
Supernus Pharmaceuticals’ outlook for the rest of the year is driven by supply chain execution, continued growth in core products, and late-stage pipeline progress.
-
Supply chain stabilization critical: Management stressed the importance of bringing a second Onapro supplier online and securing regulatory approval to ensure uninterrupted product availability. Delays or regulatory hurdles could impact revenue and market momentum, while successful execution would support forecasted growth.
-
Expanding patient reach: The company is focused on increasing patient conversions for Onepco, leveraging operational improvements and broader prescriber engagement. Management also highlighted ongoing efforts to grow the adult segment for Kelli and deepen penetration for Zirzuve, with direct-to-consumer campaigns aimed at accelerating adoption.
-
R&D pipeline advancements: Progress in late-stage clinical trials, including Phase 2b studies for SPN-820 and SPN-817, is expected to provide new growth avenues. Management noted that successful trial outcomes and timely regulatory submissions are key to expanding the company’s CNS portfolio and sustaining long-term performance.
Catalysts in Upcoming Quarters
In future quarters, the StockStory team will be watching (1) the approval timeline and onboarding progress for the second Onapro supplier, (2) prescription growth and patient conversion rates for Onepco and Kelli, and (3) clinical milestones in the SPN-820 and SPN-817 trials. Additionally, we will assess the impact of direct-to-consumer campaigns and any new licensing or collaboration agreements as signposts of execution.
Supernus Pharmaceuticals currently trades at $50.61, up from $49.19 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.